WW (WeightWatchers) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Revenue: $168 million, down 10% year-over-year.

Adjusted EBITDA: Loss of $1.8 million.

End-of-Period Subscribers:

Behavioral: 2.5 million (down 25% year-over-year).

Core+: 537,000 (up 6% year-over-year).

Clinical: 197,000 (up 51% sequentially).

Average Revenue Per User (ARPU): Increased 13% year-over-year to $20.59; Clinical ARPU over 4x higher than Behavioral ARPU.

Adjusted Gross Margin: 73.6%, near record highs.

Cash Position: Ended Q1 with $121 million in cash and equivalents.

2Strategic Updates and Business Highlights:

Transformation Strategy: Focus on integrating GLP-1 medications with behavioral support to enhance member outcomes and drive growth.

Clinical Growth: Significant growth in Clinical subscription revenue (32% year-over-year), driven by the Med+ tier, which integrates clinical capabilities with behavioral support.

Core+ Growth: Core+ subscriber growth attributed to enhanced virtual experiences, workshops led by registered dietitians and physicians, and medically tailored programs (e.g., menopause).

Marketing Strategy: Increased brand awareness for GLP-1 offerings, resulting in a 10-point increase in general awareness and attracting new members.

3Forward Guidance and Outlook:

2026 Financial Guidance: Reaffirmed revenue guidance of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million.

Clinical Revenue Growth: Expected to represent 25% to 30% of total revenue in 2026, up from 16% in 2025.

Subscriber Growth Expectations: Anticipated sequential growth in Clinical subscribers, though lower than Q1 due to seasonal normalization and adjusted marketing spend.

4Challenges and Points of Concern:

Behavioral Business Decline: Significant decline in Behavioral subscribers (down 25% year-over-year), indicating challenges in this segment.

Market Pressures: Core business continues to face secular headwinds, necessitating a recalibration of marketing strategies.

Debt Management: While cash position is stable, ongoing management of debt and interest expenses remains a focus, with a term loan interest rate of 10.5%.

5Notable Q&A Insights:

Subscriber Growth Dynamics: Q&A highlighted expectations for subscriber growth in both Behavioral and Clinical segments, with a focus on the balance between Core+ and Core offerings.

Impact of GLP-1 Medications: The introduction of oral GLP-1 medications is seen as a positive development, expected to increase access and conversion rates.

Brand Strategy Effectiveness: Marketing efforts have successfully increased awareness of WeightWatchers' GLP-1 offerings and attracted new members, with a notable percentage of Clinical subscribers being new to the platform.

Menopause Program: The menopause initiative is contributing positively to Core+ growth, marking a significant development in the company's offerings. Overall, while WeightWatchers is experiencing growth in its Clinical and Core+ segments, challenges persist in the Behavioral segment, necessitating strategic adjustments and a focus on long-term transformation.